title: Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma.
abstract: We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.
authors.affiliation: Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine , Jinju , Korea.
authors.forename: Gyeong-Won
authors.initials: GW
authors.lastname: Lee
authors.forename: Se-Il
authors.initials: SI
authors.lastname: Go
authors.forename: Seok-Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Junshik
authors.initials: J
authors.lastname: Hong
authors.forename: Yu Ri
authors.initials: YR
authors.lastname: Kim
authors.forename: Sukjoong
authors.initials: S
authors.lastname: Oh
authors.forename: Sung-Yong
authors.initials: SY
authors.lastname: Kim
authors.forename: Young Rok
authors.initials: YR
authors.lastname: Do
authors.forename: Hyewon
authors.initials: H
authors.lastname: Lee
authors.forename: Soon Il
authors.initials: SI
authors.lastname: Lee
authors.forename: Sung Hwa
authors.initials: SH
authors.lastname: Bae
authors.forename: Sung Yong
authors.initials: SY
authors.lastname: Oh
authors.forename: Moo Kon
authors.initials: MK
authors.lastname: Song
authors.forename: Won-Sik
authors.initials: WS
authors.lastname: Lee
authors.forename: Bohee
authors.initials: B
authors.lastname: Lee
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Kim
authors.forename: Min Kyoung
authors.initials: MK
authors.lastname: Kim
authors.forename: Hye Jin
authors.initials: HJ
authors.lastname: Kang
authors.forename: Jae-Sook
authors.initials: JS
authors.lastname: Ahn
authors.forename: Ho-Young
authors.initials: HY
authors.lastname: Yhim
authors.forename: Hyo Jung
authors.initials: HJ
authors.lastname: Kim
authors.forename: Seok Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Won Seog
authors.initials: WS
authors.lastname: Kim
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D000069283:Rituximab / Q000008:administration & dosage; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Diffuse large cell lymphomas; nasal cavities; paranasal sinus; rituximab